TABLE OF CONTENTS
Volume 15, Issue 4 (April 2008)
Original Articles
Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region
A Danielsson, H Dzojic, B Nilsson and M Essand
Cancer Gene Ther 15: 203-213; advance online publication, January 11, 2008; doi:10.1038/sj.cgt.7701117
An efficient liposomal gene delivery vehicle using Sendai F/HN proteins and protamine
H S Kim, J S Kim, Y K Lee, K H Koo and Y S Park
Cancer Gene Ther 15: 214-224; advance online publication, February 8, 2008; doi:10.1038/sj.cgt.7701121
Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human
S E Khorsandi, P Bachellier, J C Weber, M Greget, D Jaeck, D Zacharoulis, C Rountas, S Helmy, A Helmy, M Al-Waracky, H Salama, L Jiao, J Nicholls, A J Davies, N Levicar, S Jensen and N Habib
Cancer Gene Ther 15: 225-230; advance online publication, February 8, 2008; doi:10.1038/sj.cgt.7701119
Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer
G Kallifatidis, B M Beckermann, A Groth, M Schubert, A Apel, A Khamidjanov, E Ryschich, T Wenger, W Wagner, A Diehlmann, R Saffrich, U Krause, V Eckstein, J Mattern, M Chai, G Schütz, A D Ho, M M Gebhard, M W Büchler, H Friess, P Büchler and I Herr
Cancer Gene Ther 15: 231-240; advance online publication, January 18, 2008; doi:10.1038/sj.cgt.7701097
Catalase overexpression reduces UVB-induced apoptosis in a human xeroderma pigmentosum reconstructed epidermis
H R Rezvani, C Ged, B Bouadjar, H de Verneuil and A Taïeb
Cancer Gene Ther 15: 241-251; advance online publication, January 18, 2008; doi:10.1038/sj.cgt.7701102
Augmented transgene expression in transformed cells using a parvoviral hybrid vector
L Krüger, H Eskerski, C Dinsart, J Cornelis, J Rommelaere, U Haberkorn and J A Kleinschmidt
Cancer Gene Ther 15: 252-267; advance online publication, January 18, 2008; doi:10.1038/sj.cgt.7701113
Retroviral vectors for clinical immunogene therapy are stable for up to 9 years
C H J Lamers, P van Elzakker, B A Luider, S C L van Steenbergen, S Sleijfer, R Debets and J W Gratama
Cancer Gene Ther 15: 268-274; advance online publication, January 18, 2008; doi:10.1038/sj.cgt.7701114
